Power To The (Adcomm) People: Members Believe Votes Should More Directly Affect US FDA Decisions
Executive Summary
A survey of advisory committee members finds many believe that an overwhelmingly negative vote should prevent a product approval.
You may also be interested in...
Rare Disease Expertise On FDA Advisory Committees Gains Capitol Hill Attention
With Congress watching whether enough experts are on advisory committees for orphan drugs, the US FDA may be pressured into changes.
Advisory Committee Disagreement With US FDA On Approval Decisions An Increasingly Rare Event
A new study finds the agency only approved a product despite a negative advisory committee vote six times in six years. The overall rate of agreement between the agency and advisory committees has increased since 2015.
BrainStorm Hoping For Advisory Committee After FDA Refuses To File BLA For Its ALS Cell Therapy
BrainStorm, which has a history of antagonizing FDA with direct appeals to patients for NurOwn, tells investors that public elements of an adcomm could be ‘persuasive,’ but first step will be formal meeting request to try to overcome the RTF. Firm sees Relyvrio as template for success.